Northwest Biotherapeutics (NWBO) Receivables (2012 - 2017)
Northwest Biotherapeutics (NWBO) posted quarterly Receivables of $3.8 million for Q4 2017, little changed year-over-year from $3.8 million in Q4 2016, and little changed quarter-over-quarter from $3.8 million in Q2 2017.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Receivables (2012 - 2017) Analysis & Trends
Northwest Biotherapeutics' Receivables history runs 3 years deep, the most recent figure standing at $3.8 million for Q4 2017.
- In Q4 2017, Receivables changed 0.0% year-over-year to $3.8 million; the TTM figure through Dec 2017 stood at $3.8 million (changed 0.0% YoY), while the FY2017 annual figure was $3.8 million, changed 0.0% from the prior year.
- Receivables for Q4 2017 stood at $3.8 million, roughly flat from $3.8 million in the prior quarter.
- The five-year high for Receivables was $3.8 million in Q4 2016, with the low at $3.8 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 3.75 Mn |
| Jun 30, 2017 | 3.75 Mn |
| Dec 31, 2016 | 3.75 Mn |
| Jun 30, 2012 | 195,000.00 |